The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.Alzheimer’s Disease, Aduhelm (Drug), Labeling and Labels (Product), Drugs (Pharmaceuticals), Clinical Trials, Food and Drug Administration, Biogen Inc, Health Insurance and Managed CareRead More
